Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma
about
Metastatic disease from uveal melanoma: treatment options and future prospectsUveal melanoma as a target for immune-therapyChinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)Upcoming translational challenges for uveal melanomaImmune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review.Uveal melanoma: From diagnosis to treatment and the science in between.Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.Atypical Presentation: Metastatic Uveal Melanoma in a Young Patient without Visual Complaints.Systematic genomic and translational efficiency studies of uveal melanoma.PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib.Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma.The biology of uveal melanomaMultistep, effective drug distribution within solid tumors.Evolving systemic targeted therapy strategies in uveal melanoma and implications for ophthalmic management: a review.A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity.Update on Metastatic Uveal Melanoma: Progress and Challenges.Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives.Immune checkpoint inhibitors: a milestone in the treatment of melanoma.Ipilimumab in melanoma.Efficacy and toxicity of transarterial chemoembolization therapy using cisplatin and gelatin sponge in patients with liver metastases from uveal melanoma in an Asian population.T cell exhaustion: from pathophysiological basics to tumor immunotherapy.The Effect of Perfusate Buffering on Toxicity and Response in Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases.Anti-PD-1 antibodies in metastatic uveal melanoma: a treatment option?Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands.Pembrolizumab-Induced Pancytopenia: A Case ReportCardiotoxicity associated with CTLA4 and PD1 blocking immunotherapyLocal irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients.Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease.Recent advances in uveal melanoma treatment.Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.Current and future immunotherapies for thyroid cancer.PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma.Acute Angle Closure Precipitated by Hemorrhage and Necrosis of a Large Uveal Melanoma in the Setting of Systemic Immunomodulatory Therapy.Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
P2860
Q26738377-702EABB0-6C09-4AEB-8222-C343415196AFQ26747519-864C3E3C-4615-400E-80C1-A438FF061358Q26770492-CD160CE5-9069-454D-AF11-E8D9F8321573Q26778535-2A4427F3-54C4-49E4-A6F1-DA5179FB761BQ30235360-82813C35-88EC-4998-8D8B-455A0570199AQ30251762-A462F5C6-4728-4D0E-AD6F-7B737E089DBAQ33440852-7E91B2F5-18BA-4412-A982-CDAD8AF38AA1Q33701061-7B074120-D8D8-4DAC-A19D-8E8D8040EBC5Q33778295-75143150-56CC-431B-9704-22687F06E6D7Q33902364-8655D671-79DD-4C54-B46D-5125A1EE3B2AQ36103432-CE5A41A7-2CF0-4AFC-99EC-688CA161BAF0Q36256712-E5CBCD25-C587-4D19-8BAF-491D0CD81C85Q37012639-1E1E0FB4-36F1-45E1-B539-1E93C8155B8EQ37742632-3185CCB3-2503-400D-87B7-04CF5A904227Q38261634-9FC6F8C6-87A3-4B6A-89E4-02BDC87617D6Q38646057-AC8F7414-13A1-4A81-ADD3-3972120C8564Q38713958-C44B5AB0-E282-4A3D-A626-725D8DCA3C76Q38783505-482D7441-95C2-46D1-B88D-4BC7E1C66A4EQ38783820-C428C135-C198-46BF-B035-796E9D5CDDD9Q38798084-92EF5E58-9436-492A-B40D-F45FD465505BQ38845833-14C3E91D-947A-4E1A-82AF-C7873D178E39Q38893697-D002A1F4-2116-49CA-8514-5C826FB3D094Q38987724-8C40A259-1C1B-4460-B106-38DC00F9B7ECQ39078341-E513087F-6F2E-4BA2-A9D9-6188A96CA3E6Q39097860-69DFC1BC-130B-414E-BBB1-ACFD6EE42B10Q39390339-F881EF8F-28DC-4094-A608-9940D7C9D634Q40444939-9F137A19-2D44-46F1-B69D-9D465A9B8E62Q41136783-1BF0C5D9-6521-404A-AD28-4475CDAAA9E7Q42354162-62D2D0E4-0DF7-4886-95FC-FC487EDE3F8BQ43110773-BCD5AFEB-CDB7-4C3F-B507-E9F6647F416CQ43147493-0C7CE0A3-5B49-48DF-827A-4DC7219D5DFCQ46757961-DE99A069-5965-4AAA-BD27-9DED23A5B307Q47239043-BF9D6289-2FAF-46FA-A0B6-51B22ECB3C1EQ47571643-FD91A9B4-5D1D-48A1-850B-2033C7BE344CQ47705923-389C798E-CF33-444A-A5FB-2EEEB1066862Q47747375-7843FAEE-455F-4EBB-92DA-EF4C4B39FB08Q47781457-DCF31180-78B2-4C01-8563-2F4E1AD4D3FFQ49557900-27AC3AE5-6E59-47D1-9B31-1031A49F8E8DQ49983946-2C6D8213-22CF-4741-B500-457638A50EF2Q50057781-52BDD54F-800A-4F55-8C8E-3506DBFA6679
P2860
Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Phase II DeCOG-study of ipilim ...... with metastatic uveal melanoma
@ast
Phase II DeCOG-study of ipilim ...... with metastatic uveal melanoma
@en
Phase II DeCOG-study of ipilim ...... with metastatic uveal melanoma
@nl
type
label
Phase II DeCOG-study of ipilim ...... with metastatic uveal melanoma
@ast
Phase II DeCOG-study of ipilim ...... with metastatic uveal melanoma
@en
Phase II DeCOG-study of ipilim ...... with metastatic uveal melanoma
@nl
prefLabel
Phase II DeCOG-study of ipilim ...... with metastatic uveal melanoma
@ast
Phase II DeCOG-study of ipilim ...... with metastatic uveal melanoma
@en
Phase II DeCOG-study of ipilim ...... with metastatic uveal melanoma
@nl
P2093
P2860
P50
P3181
P1433
P1476
Phase II DeCOG-study of ipilim ...... with metastatic uveal melanoma
@en
P2093
Alexander Enk
Bastian Schilling
Eckhart Kämpgen
Elisabeth Livingstone
Julia Vaubel
Leonie Bluhm
Lisa Zimmer
Michael Fluck
Peter Mohr
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0118564
P407
P577
2015-01-01T00:00:00Z